Transgene Won’t Sign TG4040 Partnership Soon, CEO Says

Transgene SA is reviewing the strategy for its experimental hepatitis C treatment and is unlikely to find a partner for the therapeutic vaccine soon, Chief Executive Officer Philippe Archinard said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.